title: Expanding role of percutaneous ablative and consolidative treatments for musculoskeletal tumours.
abstract: Interventional approaches to musculoskeletal tumours have significantly changed over the last several years, and new treatments continue to be developed. All ablative modalities are currently applied to the treatment of bone tumours, including radiofrequency, cryo-, microwave, and laser ablation devices. Indications for ablation of bone and soft-tissue tumours have expanded beyond palliation of painful bone metastases and eradication of osteoid osteomas to the local control of oligometastatic disease from a number of primary tumours and ablation of desmoid tumours. In addition, tools for consolidation of bone tumours at risk of pathological fracture have also expanded. With these developments, ablation has become the primary treatment for osteoid osteomas and, at some institutions, desmoid tumours. It may be the primary or secondary treatment for palliation of painful bone tumours, frequently used in patients with pain refractory to or recurrent after radiation therapy. It is used as a treatment for limited metastatic disease or for metastases that grow disproportionately in patients with multifocal metastases, either in combination with systemic therapy or to reserve systemic therapy and its toxicity for more widespread disease progression. Moreover, percutaneous methods to consolidate bone at risk of fracture have become more commonplace, aided by techniques using materials beyond typical bone cement.
authors.affiliation: Department of Radiology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA. Electronic address: kurup.anil@mayo.edu.
authors.forename: A N
authors.initials: AN
authors.lastname: Kurup
authors.affiliation: Department of Radiology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
authors.forename: M R
authors.initials: MR
authors.lastname: Callstrom
mesh_terms: D055011:Ablation Techniques / Q000009:adverse effects / Q000379:methods*; D001859:Bone Neoplasms / Q000473:pathology / Q000601:surgery*; D003131:Combined Modality Therapy; D006801:Humans; D059146:Metastasectomy; D019042:Muscle Neoplasms / Q000473:pathology / Q000601:surgery*; D009362:Neoplasm Metastasis; D012307:Risk Factors